Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection | Zendy

Reto Nüesch | Zendy; Jintanat Ananworanich | Zendy; Preeyaporn Srasuebkul | Zendy; Ploenchan Chetchotisakd | Zendy; Wisit Prasithsirikul | Zendy; Wirat Klinbuayam | Zendy; Apicha Mahatharit | Zendy; Thidarat Jupimai | Zendy; Kiat Ruxrungtham | Zendy; Bernard Hirschel | Zendy

Open Access

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection

Author(s) -

Reto Nüesch,

Jintanat Ananworanich,

Preeyaporn Srasuebkul,

Ploenchan Chetchotisakd,

Wisit Prasithsirikul,

Wirat Klinbuayam,

Apicha Mahatharit,

Thidarat Jupimai,

Kiat Ruxrungtham,

Bernard Hirschel

Publication year - 2008

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e3282f303bf

Subject(s) - emtricitabine , medicine , hepatitis b virus , virology , tenofovir , lamivudine , hepatitis b , human immunodeficiency virus (hiv) , virus

Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research